ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Emerging Options in Osteoporosis
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Presenters
Facebook Comments